Insight Advisors LLC PA increased its stake in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Free Report) by 59.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 21,177 shares of the company’s stock after purchasing an additional 7,861 shares during the quarter. Insight Advisors LLC PA owned approximately 0.24% of Global X Genomics & Biotechnology ETF worth $221,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GNOM. Portland Global Advisors LLC increased its stake in shares of Global X Genomics & Biotechnology ETF by 0.6% during the 1st quarter. Portland Global Advisors LLC now owns 242,090 shares of the company’s stock worth $2,755,000 after purchasing an additional 1,450 shares during the last quarter. Capital Analysts LLC boosted its stake in shares of Global X Genomics & Biotechnology ETF by 8.9% during the 4th quarter. Capital Analysts LLC now owns 18,732 shares of the company’s stock worth $217,000 after acquiring an additional 1,537 shares in the last quarter. Centaurus Financial Inc. increased its holdings in shares of Global X Genomics & Biotechnology ETF by 14.6% during the 4th quarter. Centaurus Financial Inc. now owns 12,738 shares of the company’s stock valued at $147,000 after acquiring an additional 1,624 shares during the last quarter. McGuire Investment Group LLC raised its stake in shares of Global X Genomics & Biotechnology ETF by 6.7% in the 1st quarter. McGuire Investment Group LLC now owns 58,651 shares of the company’s stock valued at $667,000 after acquiring an additional 3,696 shares in the last quarter. Finally, James J. Burns & Company LLC lifted its holdings in Global X Genomics & Biotechnology ETF by 35.6% in the 4th quarter. James J. Burns & Company LLC now owns 18,479 shares of the company’s stock worth $214,000 after purchasing an additional 4,848 shares during the last quarter. 56.95% of the stock is owned by hedge funds and other institutional investors.
Global X Genomics & Biotechnology ETF Stock Up 1.5 %
GNOM stock traded up $0.17 during midday trading on Tuesday, hitting $11.18. 17,278 shares of the company traded hands, compared to its average volume of 63,597. Global X Genomics & Biotechnology ETF has a twelve month low of $8.63 and a twelve month high of $12.53. The stock has a market capitalization of $83.18 million, a price-to-earnings ratio of -4.71 and a beta of 1.03. The business has a 50 day simple moving average of $10.85 and a 200-day simple moving average of $10.91.
Global X Genomics & Biotechnology ETF Company Profile
Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.
Recommended Stories
- Five stocks we like better than Global X Genomics & Biotechnology ETF
- Pros And Cons Of Monthly Dividend Stocks
- Buy On Holdings Stock Before the Market Catches Its Second Wind?
- The 3 Best Fintech Stocks to Buy Now
- 3 High-Potential Stocks That Could Turn Into Multi-Baggers
- How to buy stock: A step-by-step guide for beginners
- CEO Swap: Starbucks Surges 22% on Hiring New CEO From Chipotle
Receive News & Ratings for Global X Genomics & Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global X Genomics & Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.